[Media Releases] AstraZeneca, LegoChem Biosciences To Co-Develop Novel Antibiotics (AsianScientist, 24 Dec 2012)
Title: AstraZeneca, LegoChem Biosciences To Co-Develop Novel Antibiotics Publication: Asian Scientist Date: 24 Dec 2012 URL: link to website
AstraZeneca has licensed an antibiotic drug candidate from South Korea’s LegoChem Biosciences to treat drug-resistant bacterial infections.
About LegoChem Biosciences
LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC). |